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ABSTRACT 
 
Metoclopramide hydrochloride is a dopaminereceptor antagonist, used mostly for stomach 
and esophageal problems as it is a prokinetic agent. The aim of the present study was to 
design and evaluate the suppositories of Metoclopramide HCl.   
Six different, rectal suppositories were developed by fusion (pour-moulding) method by 
employing various hydrophilic and hydrophobic polymeric bases like gelatin, PEG-400 and 
hydrogenated vegetable oilusing propylene glycol as plasticizer and beeswax as hardening 
agent.  Metoclopramide HCl suppositories were evaluated for appearance, weight variation, 
drug content uniformity, liquefaction time and temperature, micro-melting range, 
disintegration and in-vitro release study.   
The in-vitro release rate data was evaluatedstatistically and was found that from all the 
formulations the drug release is by diffusion mechanism. Optimum formulation of batch S1 
has shown 83.427% Metoclopramide HCl in a study of 2 hrs. These drug release results are 
supported by the disintegration time of suppositories. Lesser the disintegration time faster the 
drug release. All formulations has shown zero, first and Higuchi release kinetics. 
The result suggests that the Metoclopramide HCl suppositories can be prepared by employing 
hydrophilic and hydrophobic polymers. 
 
Keywords: Hydrogenated vegetable oil, in-vitro release study, Metoclopramide 
hydrochloride, suppositories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
A conventional suppository is a medicated solid dosage form whichmelts or softens at body 
temperature. Suppositories are medicated solid bodies suitably shaped for rectal 
administration
1
. They offer an alternate form of oral medication for systemic action in 
patients who are in coma or who cannot tolerate oral medication due to periodical episodes of 
nausea and vomiting or pathological conditions of gastrointestinal tract. Rectal route of 
administration is specifically useful for infants and children who have difficulty in 
swallowing oral medicine
2
. 
Human rectum remains to be a relatively unexplored route of drug delivery despite its 
potential as a non- invasive route of drug administration
3
. Drug administered in suppository 
form can produce not only local effect but also systemic therapeutic action. The presence of 
dense network of blood vessels has made the rectum an excellent route of drug delivery for 
both systemic and local effect. Blood draining thelower part of the rectum largely by-passes 
the liver so that drugs showing a high first-pass metabolism when given orally are more 
effectively absorbed when administered rectally
4
.  
Metoclopramide hydrochloride, a dopamine receptor antagonist is indicated in the treatment 
of gastro oesophageal reﬂux disease, nausea and vomiting. In long term therapy, it is used for 
emesis caused due to chemotherapy in cancer patient
5,6,7
.  
The aim of this study was to formulate and evaluate sustained release suppositories for 
metoclopramide HCl to avoid first pass metabolismand thus improve bioavailability and 
avoid vomiting limitation of oral route. Suppositories were tested in order to determine 
weight variation, hardness, friability, drug content uniformity and the release characteristics 
of metoclopramide HCl from suppositories.  
MATERIALS AND METHODS 
Metoclopramide HCl was obtained from Unicure Pharmaceutical Limited, Ogun State, 
Nigeria. Beeswax and gelatin were obtained from Barata Pharmaceuticals, Rivers State 
Nigeria. HPMC(K4M) and Propylene glycol were obtained from Dana Drugs Limited, Lagos, 
Nigeria. Methyl Paraben and PEG 400 were obtained from NHC Pharmaceuticals Ltd, Lagos, 
Nigeria. All other chemicals used were of analytical reagent grade. 
Calibration of Mould and displacement value 
Before preparing the suppositories, the mould should be calibrated because the moulds may 
vary in their capacity. The base was melted alone and then filled into the mould and weighed 
after removing the suppositories; the mean weightwas taken as true capacity of the mould. 
The procedure was repeated for different bases. The calibrated mould capacities ranged from 
1.02 to 1.195 g for hydrogenated vegetable oil suppositories and 1.224 to 1.329 g for gelatin 
base suppositories
8
. 
Preparation of suppositories 
Hydrogenated vegetable oil Metoclopramide HCl suppositories were prepared using fusion 
(pour-moulding) method. Hydrogenated vegetable oil was taken in a china dish and melted. 
Metoclopramide HCl was dispersed in the melted oil; after complete dispersion, the melted 
base along with drug was poured into the pre-calibrated mould (rapid coolingshould be 
avoided as it results in holing of the suppositories).  
For the preparation of gelatin Metoclopramide HCl suppositories, gelatin was added to water 
and heated. In the mixture of propylene glycol and PEG 400, accurately weighed amounts of 
drug and preservative (methyl paraben) were added. This solution was then added to the 
solution of gelatin and heated on water bath at 70- 80°C, stirred to yield homogeneous 
solution and the solution transferred into the pre-calibrated mould and cooled immediately 
which is very essential for gelatin suppositories
9
. The prepared suppositories were wrapped in 
aluminum foil and stored under refrigeration. The composition of all batches of suppositories 
is shown in Table 1. 
  
Table 1: Table 1: Composition of Metoclopramide HCl suppositories formulations. 
S. N.  
 
Ingredients  
 
S1  
 
S2  
 
S3  
 
S4  
 
S5  
 
S6 
1 
Metoclopramide 
HCl (mg) 
15 
15 15 15 15 15 
2 
Hydrogenated 
vegetable oil (g) 
-  15  -  16  -  
15 
3 Beeswax (g)  2.48  2.52 1.96  1.82 1.92  2.46 
4 Gelatin (g)  6.00  -  5.00 - 5.00 - 
5 HPMC(K4M) -  3.00  -  6.00 5.00 - 
6 
Propylene glycol 
(g)  
6  8  10 7 -  
8 
7 Methyl Paraben (g)  0.3  0.3  0.3  0.3 -  0.3 
 
PEG 400 (g) 3.00  - 4.5 - 6.00 - 
8 
Distilled Water 
(ml)  
5.0  5.0 5.0 5.0 5 
5 
 
 
CHARACTERIZATION OF SUPPOSITORIES 
Table 2: Evaluation of Metoclopramide HCl suppositories for various parameters 
Code Visual characterization of the formulations 
Drug 
Content 
(mg) 
Weight 
variation 
(mg) 
 
Fissuring Pitting 
Fat 
blooming 
Exudation 
Migration 
of active 
ingredient 
 
S1  NO  NO  NO  NO  NO  98±0.13 1.13±0.08 
S2 NO  NO  NO  NO  NO  97±0.32 1.15±0.12 
S3 NO  NO  NO  NO  NO  96±0.45 1.16±0.36 
S 4 NO  NO  NO  NO  NO  94±0.35 1.18±0.48 
S5 NO  NO  NO  NO  NO  99±0.08 1.14±0.63 
S6 NO NO NO NO NO 95±0.86 1.21±0.41 
 
 
Table 3: Physico-chemical characterization of Metoclopramide HCl suppositories 
Code  
 
 
 
Friability 
(%) 
 
 
Hardness 
(kg/cm
2
) 
 
 
Breaking 
strength 
(gm) 
 
Liquefaction 
time (min.) 
 
 
Melting 
time 
(min.) 
 
Disinteg
ration 
time 
(min) 
S1  0.32±0.12  2.8±0.58  424±15.2  1:25±0:03  23:10±0:02 38±0.05 
S2 0.41±0.15  2.3±0.37  425±15.2  1:34±0:15  25:28±0:01 39±0.08 
S3 0.43±0.09  2.4±0. 82 428±15.4  1:36±0:07  26:43±0:03 41±0.12 
S 4 0.46±0.22  3.2±0.51 432±16.2  1:42±0:24  27:29±0:04 42±0.21 
S5 0.45±0.31  3.6±0. 64 434±16.4  1:41±0.37  28:48±0:01 39±0.19 
S6 0.39±0.43 2.9±0. 38 431±12.5 1:49±0:23 26:57±0:05 40±0.42 
 
 
Visual characterization 
The randomly selected Metoclopramide HCl suppositories (six suppositories from each 
batch) were cut longitudinally and examined with the naked eye (subjective evaluation) to 
assess the verified the homogeneity of surface appearance and color of suppositories by 
Absence of fissuring, Absence of pitting, Absence of fat blooming, Absence of exudation, 
Absence of migration of the active ingredients. This last test is best accomplished by taking a 
 longitudinal section of the suppository to verify thehomogeneity of the active ingredient(s) 
within the mass
10
. 
Breaking strength 
The breaking strength or crushing strength of Metoclopramide HCl suppositories was 
determined for measuring fragility or brittleness of suppositories, which assess whether the 
suppositories will be able to withstand the hazards of packing, transporting and normal 
handling or not. A plastic disc was fixed horizontally on to one end of the iron rod to which 
weight are applied and other end had been reduced to sharp point. The sample suppository 
was placed between the metal plate and the sharp end of the iron rod and placing 200 g 
weights on to the pan. At 1-minute intervals, 50 g weights are added, and the weight at which 
the suppository collapses in the breaking point, or theforce that determined the fragility of 
brittleness characterization of the suppositories
11
. 
Mechanical strength (hardness) 
A physical characteristic such as mechanical strength (hardness test) of Metoclopramide HCl 
suppositories was determined. The hardness of a cylindrical portion (9.6 mm thickness) of 
suppository, which was obtained by cutting the middle portion of the suppository, was 
measured in its diameter direction with a Monsanto hardness tester
12
. 
Weight variation 
Twenty Metoclopramide HCl suppositories were weighed and average weight was calculated. 
Each suppository was then individually weighed by using digitalbalance. Not more than 2 of 
the individual masses deviate from the average mass by more than 5 %
13
. 
Friability 
Twenty Metoclopramide HCl suppositories were weighted and placed in the plastic chamber 
of Roches Friabilator. The chamber was then rotated for 4 minutes at 25 rpm (a total of 100 
revolutions). During each revolution suppositories fall from a distance of 6 inches. After 100 
revolutions the suppositories were removed and weighed again
14
. 
% F=((Wi-Wf ))/Wi X 100 
 
Where, Wi was the initial weight of the suppositories before friability testing, Wf was the 
weight of suppositories after the testing.  
Melting point 
The melting time is a critical factor in the determination of the release rate of the active 
ingredient(s) from the suppository. This test is also known asmacro melting range test. 
During this test, the time taken for the entire suppository to melt or disperse is measured 
when immersed in a water bath maintained at constant temperature (37±1
o
C). The time 
required for the whole Metoclopramide HCl suppository to melt or disperse in the 
surrounding water was noted
15
. 
Liquefaction or softening time 
This important element indicates the physical behaviour of a suppository subjected to its 
maximum functional temperature (37°C). It consists of a U-tube partially submersed in a 
constant temperature water bath. This can be carried out at varioustemperatures from 35.5 to 
37oC, as a quality control check and can also be studied as a measure of physical stability 
over time. The softening test measures the liquefaction time of rectal suppositories. In this, to 
measures the time necessary for a suppository to liquefy under pressure similar to those found 
in the rectum in the presence of phosphate buffer pH 7.4 (5.0 ml) surrounding the water at 
body temperature
16
. 
Drug Content 
Six Metoclopramide HCl suppositories of each formulation were cut into small pieces. 
Phosphate buffer (pH 7.4) was added up to the mark and the volumetric flask was heated 
slightly to melt the suppository. The suppository was then allowed to cool. After filtration the 
 content of drug was determined using a UV/Visiblespectrophotometer by measuring 
absorbance of the 272 nm for metoclopramide HCl. Concentrations were determined using 
standard calibration curve equations
17
.  
In vitro drug release tests 
In vitro release test was carried out using USP type1 rotating basket apparatus (Pharma-test, 
Germany). Each Metoclopramide HCl suppository was placed in basket and lowered into a 
flask containing 900 ml of phosphate buffer solution (pH 7.4). The basket was rotated at 50 
rpm at a constant temperature 37±0.5
o
C. Aliquots of 3 ml were withdrawn at appropriate time 
intervals for a period of 1 h and immediately replaced by 3 ml fresh phosphate buffer. The 
amount of drug released in the time course from suppositories was spectrophotometrically 
determined after a suitable dilution with phosphate buffer at 272 nm. For each formulation, 
the experiments were carried out in triplicate
18
. 
Drug Release Kinetics 
To study the release kinetics, data obtained from all Metoclopramide HCl suppositories 
formulations were applied to kineticmodels such as zero order, first order and Higuchi. The 
release rate constants (k), and determination coefficients (R
2
) were calculated by means 
Microsoft Excel, 2016 version
19
. 
 
 
Figure 1: In vitro release profile of Metoclopramide HCl from different suppositories 
formulations 
 
 
 
 
Table 4: Release kinetics of Metoclopramide HCl from suppositories 
Parameter S1 S2 S3 S4 S5 S6 
Zero order 
R
2
 0.87 0.85 0.98 0.96 0.94 0.89 
K0 0.75 0.68 0.59 0.63 0.58 0.64 
First order 
R
2
 0.91 0.90 0.88 0.87 0.94 0.89 
K1 0.02 0.01 0.03 0.02 0.01 0.01 
Higuchi model 
R
2
 0.98 0.97 0.95 0.94 0.96 0.93 
KH 1.83 1.72 0.9 0.88 1.23 1.36 
R
2
: Determination coefficient. k: Release rate constant  
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 RESULTS AND DISCUSSION 
Six suppositories of Metoclopramide HCl suppositories were prepared by fusion method 
using hydrogenated vegetable oil and gelatin as bases. Bees wax was used to increase the 
melting point of hydrogenated vegetable oil and propylene glycol was used as plasticizer. The 
prepared suppositories had a glossy, smooth surface, without showing cracks, white or 
coloured spots, air bubbles, fat blooming or exudation.  
The prepared suppositories were evaluated for appearance, weight variation, drug content 
uniformity, liquefaction time and temperature, micro-melting range, disintegration and in-
vitro release study.  The results of visual and physicochemical characterization are shown in 
table 2 and 3. All the formulations were found to have homogeneous drug distribution with 
content uniformity, weight uniformity and sufficient mechanical strength to withstand 
abrasive forces causing disintegration of drug loaded formulation.  
The width and length of the randomly selected suppositories was found to be good 
homogeneity.  The weightvariation studies for all suppositories were found to be within the 
acceptable range of <5 %.which indicates that calibration of mould was perfect
20
. 
All the prepared suppositories showed uniformity of drug content was within the permissible 
range (95 to100 %) indicating uniformity of drug dispersion in suppositories. The friability 
was found to be within acceptable limits (less than 1 %). The suppositories should have good 
mechanical strength for handling and transportation. All suppositories were having good 
mechanical strength in the range of (2.3±0.37 to 3.6±0. 64 kg/cm
2
) showing optimum 
hardness
21
. 
The liquefactiontime was studies as a measure of physical stability over time. The estimation 
of drug content in the formulation revealed that the drug was distributed uniformly with low 
coefficient of variations, indicating batch to batch consistency. The crushing or breaking 
strength was determined for measuring fragility or brittleness of the suppositories, which 
assess whether the suppositories will be able to withstand hazards of packaging, transporting 
and normal handling or not
22
.  The formulated rectal suppositories were smooth and fine in 
texture with mechanical strength (hardness). 
Suppositories liquefaction time range was found to be 1:25±0:03-1:49±0:23 min. The 
softening and disintegration times varied largely, depending on the properties of the 
lipophilic base and on its interaction with the active pharmaceutical ingredient, having weak 
or non acidic properties. The disintegration test for suppositories ranges in between 38±0.05-
42±0.21 min. The in vitro release profile of lornoxicam from different bases are shown table 
4.  Maximum release  83.427%  was shown by the suppositories of batch S1and minimum 
60.39%  by the batch S2 in a study of 2 hr. Thesedrug release results are related with 
disintegration time of suppositories and is inversely proportional to disintegration time
23
. In 
general release is inversely proportional to the lipophilicity of the base
24
. Suppositories has 
shown drug release by zero, first and Higuchi kinetic model (table 4). 
 
Conclusion 
 
The influence of the composition on the results of the pharmacotechnical evaluations and on 
in vitro release parameters was assessed for six different prepared rectal suppositories of 
Metoclopramide HCl.  
This study showed ultimate results with respect to the physical characteristics of 
suppositories (especially hardness and disintegration time) and in vitro drug release studies.  
The prepared suppositories of sustains the release of Metoclopramide HCl, melts at 
physiological temperature and has prolonged retention time by adhering to rectal mucosa. 
About 83.427% Metoclopramide HCl wasreleased from S1 in a study of 2 hrs. On the basis 
 of release and other parameters the formulation of batch S1, consisting of gelatin is 
considered to be optimum formulation.  
The kinetic particularities were adequately described bythe zero, first and Higuchi model, 
confirming the combined role of the contact surface and diffusional resistance. On the basis 
of different results it can be concluded that rectal suppositories of Metoclopramide HCl can 
be prepared by utilizing hydrogenated vegetable oil and gelatin. However, in vivo studies are 
required to ascertain the results obtained with in-vitro drug release studies. 
 
REFERENCES 
1. Moghimipour E, Ali MD, Fatemeh MA. Characterization and in-vitro evaluation of 
piroxicam suppositories. Asian J Pharm 2009; 2(3): 92-8. 
2. Sankar VR, Reddy YD, Reddy GH, Reddy GSK. Formulation and In-vitro 
characterisation of sustained release metronidazole cocoa butter suppositories. Inventi 
Impact: Pharm Tech 2012; (4): 275-80. 
3. Varshney HM, Tanwar YS. Formulation, physicochemical characterization and in-
vitro evaluation of flurbiprofen sodium suppositories. J Pharm Res 2010; 3(3): 561-5. 
4. Azechi, Y, Ishikawa, K, Mizuno,N, and Takahashi, K. Sustained-release of diclofenac 
from polymercontaining suppositories and the mechanisms involved. Drug Dev. Ind. 
Pharm. 2000; 26: 1177-1183 
5. Hibbs, AM; Lorch, SA (Aug 2006). "Metoclopramide for the treatment of 
gastroesophageal reflux disease in infants: a systematic review". Pediatrics. 118 (2): 
746–52. 
6. Henzi I, Tramèr MR, Metoclopramide for the Control of Postoperative Nausea and 
Vomiting. pp 161-168 in Antiemetic Therapy. Donnerer J (ed). Karger, 2003. 
7. Matok, I.; Gorodischer, R.; Koren, G.; Sheiner, E.; Wiznitzer, A.; Levy, A. (2009). 
"The Safety of Metoclopramide Use in the First Trimester of Pregnancy". New 
England Journal of Medicine. 360 (24): 2528–2535. 
8. Ahmed MG, Khaksa VG, Udupa N, Paranjyothy KLK. Formulation release 
characteristic and evalution of nimesulide suppositories. Indian J Pharm Sci 2000; 
63(3): 196-9. 
9. Ofoefule SI, Ibezim EC, Esimone OC, Pepple MN, Njoku CN, Orisakwe EO. 
Bioavailability of metronidazole in rabbits after administration of a rectal suppository. 
Am. J. Ther. 2004;11(3):190-3. 
10. Kaewnopparat S., Kaewnopparat N. Formulation and evaluation of vaginal 
suppositories containing Lactobacillus. J. World Academy of Science, Engineering 
and Technology. 2009; 55: 25-28. 
11. Ryu JM, Chung SJ, Lee MH, Kim CK, Shim CK. Increased bioavailability of 
propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J. 
Control. Release 1999;59(2):163-72. 
12. Yun M.O., Choi H.G., Kim C.K. Development of thermoreversible insulin liquid 
suppository with sodium salicylate. Int. J. Pharm. 1999, 189, 137-145. 
13. Samy EM, Hassan MA, Tous SS, Rhodes CT. Improvement of availability of 
allopurinol from pharmaceutical dosage forms I-suppositories. Eur. J. Pharm. 
Biopharm. 2000; 49(2):119-27.  
14. Itoh S, Teraoka N, Matsuda T, Okamoto K, Takagi T, Oo C, Kao HD. Reciprocating 
dialysis method: periodic tapping improved in-vitro release/dissolution testing of 
suppositories. Eur. J. Pharm. Biopharm., 2006; 64: 393-398. 
15. Noordin MI and Chung LY: Palm Kernel Oil Blends as Suppository Bases In The 
Delivery Of Aspirin. Journal of the University Malaya of Medical Centre 2007; 
10:43-50. 
 16. Zawar LR, Bhandari GS. Formulation and evaluation of sustained release ondansetron 
poloxamer based solid suppositories. Journal of Applied Pharmaceutical Science 
2012; 2 (7): 186-90. 
17. Victoria MM and David CJ. Thermal and rheological study of lipophilic ethosuximide 
suppositories. Eur. J. Pharm. Sci. 2003; 19: 123-128. 
18. Nilüfer T, Dilek E: Preparation And In Vitro Evaluation Of Sustained Release 
Suppositories Of Indomethacine. Journal Faculty of Pharmacy Ankara. 1998; 27:11-
21. 
19. Rcadon N, Ragazzi E, Ragazzi E. Effects of drug solubility on In-vitro availability 
rate from suppositories with polyethylene glycol excipients. Pharmazie 2001; 56(2): 
163-7. 
20. Uehara S., Monden K., Nomoto K., Seno Y. A pilot study evaluating the safety and 
effectiveness of lactobacillus vaginal suppositories in patients with recurrent urinary 
tract infection. Int. J. Microbiol. Agent. 2006; 285: 530-534. 
21. Chicco D, Grabnar I, Skerjanec A, Vojnovic D, Maurich V, Realdon N, Ragazzi E, 
Belic A, Karba R and Mrhar A. Correlation of in vitro and in vivo paracetamol 
availability from layered excipients suppositories. Int. J. Pharm. 1999; 189: 147-160. 
22. Akala EO, Adedoyin A, Ogunbona FA. Suppository formulation of amodiaquine: In 
vitro release characteristics, Drug Dev. Ind.Pharm., 1991, 17, 303 –307. 
23. Toshiaki N, Masao S, Akira K, Masaharu K, Takashi F, Shigeo K, NobuoT : 
Investigation of sustained-release suppository of sodium diclofenac in humans. 
International Journal of Pharmaceutics, 1986; 33:181-186. 
24. Hanaee J, Javadzadeh Y, Taftachi S, Farid D, Nokhodchi A. The role of various 
surfactants on the release of salbutamol from suppositories. Farmaco. 2004; 59: 903–
906. 
 
